What's happening?


Published October 2, 2015

XSpray Microparticles receives 18 million SEK investment

STOCKHOLM – October 2, 2015  The 18 million SEK investment will be used to finance the clinical development of XSpray’s lead compound, XS-004, developed with XSpray’s proprietary HyNap™ drug formulation technology. XS-004 is based on a well-known protein kinase inhibitor (PKI) compound.

Press release Recipharm – Xspray 151002 web